IN significantly reduced disease severity in animal models of IBD by suppressing inflammation through balancing innate and adaptive immunity, regulating the AhR/CYP1A1 signaling pathway, and modulating gut microbiota composition. This evidence concerns the gene CYP1A1 and inflammatory bowel disease.